Anakinra: An interleukin-1 receptor antagonist for treatment of rheumatoid arthritis

Formulary

Volumn 36, Issue 3, 2001, Pages 191-203

  Small, R E ^a   Wixted, M A ^a   Roberts, W N ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; INJECTION SITE; JOINT DESTRUCTION; NEUTROPENIA; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 0035100828     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Rheumatoid arthritis: Pathophysiology and implications for therapy
2. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis
3. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1
4. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
5. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
6. Population pharmacokinetics of recombinant interleukin-1 receptor antagonist (anakinra) in subjects with rheumatoid arthritis (RA)
7. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis - Radiologic progression and correlation of Genant and Larsen scores
8. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
9. Development and validation of the European League Against Rheumatism Response Criteria for Rheumatoid Arthritis: Comparison with the Preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria
10. Update in rheumatology
11. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films
12. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs
13. Methods of assessing radiographic change in rheumatoid arthritis
14. Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis
15. Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the second 6 months of treatment for patients with rheumatoid arthritis
16. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs
17. Treatment of interleukin-1 receptor antagonist in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients
18. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans
19. IL-1-RA improves health-related quality of life as measured by the Health Assessment Questionnaire
20. Characterizing the health-related quality of life effects of IL-1-RA therapy as measured by the Health Assessment Questionnaire
21. Hospital utilization in rheumatoid arthritis: Effects of joint replacement and medical complications
22. Predictors of hospital utilization in joint replacement - Does having RA make a difference?
23. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
24. ACR focuses on new and emerging arthritis drugs